Point Biopharma Global Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Point Biopharma Global Inc (PNT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Point Biopharma Global Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 244M vs 57,338M combined for its competitors (0.4% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-95.4% annualized vs trailing 12 months), vs decelerating (-98.9%) for its tracked peer group.
- Profitability: Its -888.0% net margin compares with -715.2% for the peer group.
- Peer revenue share: Point Biopharma Global Inc accounted for 1.8% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $2.44M compares with $0.73M for the peer group (3.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PNT Sales vs. its Competitors, Q3 2023
With a net margin of -887.97 %, Point Biopharma Global Inc reported lower profitability than its competitors (-715.16 %).
Point Biopharma Global Inc generated 1.82 % of the combined sales of its peer group.
API endpoints for this dataset
Point Biopharma Global Inc vs. its Competitors, Q3 2023
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Point Biopharma Global Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Point Biopharma Global Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Point Biopharma Global Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (100) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Point Biopharma Global Inc's competitor groups requires a Commercial License.
Point Biopharma Global Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Point Biopharma Global Inc | Yes | - | - | No |
| Competitors combined (45) | ||||
| High-Confidence Competitors (107) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PNT Stock Performance relative to its Competitors
PNT Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Rallybio Corporation | 282.9% | Outperformed |
| 2 | Edgewise Therapeutics inc | 282.9% | Outperformed |
| 3 | Merus N v | 282.9% | Outperformed |
| 4 | Boundless Bio Inc | 282.9% | Outperformed |
| 5 | Roivant Sciences Ltd | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Point Biopharma Global Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Point Biopharma Global Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Point Biopharma Global Inc |
1,322.07 | 243.69 |
 Novartis Ag |
319,173.30 | 56,674.00 |
 Roivant Sciences Ltd |
29,688.79 | 7.53 |
 Merus N v |
6,810.81 | 56.61 |
 Edgewise Therapeutics inc |
5,009.87 | - |
 Forte Biosciences Inc |
1,634.43 | - |
| SUBTOTAL | 370,210.68 | 57,601.24 |
Sign in to see all competitors of Point Biopharma Global Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Point Biopharma Global Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Point Biopharma Global Inc's Competitors Named by the Company
Competitive relationships identified from Point Biopharma Global Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Passage Bio Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Biogen Inc | Company report | 85% |
| Agentix Corp | Company report | 85% |
| Petvivo Holdings Inc | Company report | 85% |
| Regencell Bioscience Holdings Limited | Company report | 85% |
| Fibrobiologics Inc | Company report | 85% |
| Intensity Therapeutics Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Mangoceuticals Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Crispr Therapeutics Ag | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Corbus Pharmaceuticals Holdings Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Halozyme Therapeutics Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Denali Therapeutics Inc | Company report | 85% |
| Roche Holding AG | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Neurosense Therapeutics Ltd | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Shuttle Pharmaceuticals Holdings Inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Bristol-Myers Squibb | Company report | 85% |
| Fusion Pharmaceuticals Inc | Company report | 85% |
| Novo Nordisk A | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Palatin Technologies Inc | Company report | 85% |
| Maia Biotechnology Inc | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Altimmune inc | Company report | 85% |
| Beone Medicines Ltd | Company report | 85% |
| Bicycle Therapeutics Plc | Company report | 85% |
| Compass Therapeutics Inc | Company report | 85% |
| Contineum Therapeutics Inc | Company report | 85% |
| Redwoods Acquisition Corp | Company report | 85% |
| Definium Therapeutics Inc | Company report | 85% |
| Nyxoah Sa | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| BGNE | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Coya Therapeutics Inc | Company report | 85% |
| Cytosorbents Corporation | Company report | 85% |
| MNMD | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Innate Pharma Sa | Company report | 85% |
| Bicara Therapeutics Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Reshape Lifesciences Inc | Company report | 85% |
| Journey Medical Corp | Company report | 85% |
| Kodiak Sciences | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Opthea | Company report | 85% |
| Prime Medicine Inc | Company report | 85% |
| Outlook Therapeutics | Company report | 85% |
| Generation Bio Co | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Ocular Therapeutix | Company report | 85% |
| REGENXBIO | Company report | 85% |
| Jupiter Neurosciences Inc | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Point Pharmaceuticals | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Macrogenics Inc | Company report | 85% |
| Cytokinetics Incorporated | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Qsam Biosciences Inc | Company report | 85% |
| Lumos Pharma Inc | Company report | 85% |
| Peak Bio Inc | Company report | 85% |
| Aclaris Therapeutics Inc | Company report | 85% |
| Gossamer Bio Inc | Company report | 85% |
| Xeris Biopharma Holdings Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Invivyd Inc | Company report | 85% |
| Biorestorative Therapies Inc | Company report | 85% |
| Abvc Biopharma Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Opus Genetics Inc | Company report | 85% |
| Mannkind Corporation | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Molecular Partners Ag | Company report | 85% |
| OCUP | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Graybug Vision | Company report | 85% |
| Janssen | Company report | 85% |
| Inflarx N V | Company report | 85% |
| 4D Molecular Therapeutics | Company report | 85% |
| Better Therapeutics Inc | Company report | 85% |
| Hoffmann-La Roche Ltd. | Company report | 85% |
| UCB | Company report | 85% |
| Bayer | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Scholar Rock | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Fresh Tracks Therapeutics Inc | Company report | 85% |
| Alector Inc | Company report | 85% |
| Exagen Inc | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Viracta Therapeutics Inc | Company report | 85% |
| Harmony Biosciences Holdings inc | Company report | 85% |
| Acceleron Pharma inc | Company report | 85% |
| Generic Pharmaceuticals | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Alzamend Neuro Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Incannex Healthcare Inc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Vistagen Therapeutics Inc | Company report | 85% |
| Moonlake Immunotherapeutics | Company report | 85% |
| Sangamo Therapeutics Inc | Company report | 85% |
| Gsk Plc | Company report | 85% |
| Incyte Corporation | Company report | 85% |
| Esperion Therapeutics Inc | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Argenx Se | Company report | 85% |
| Organon and Co | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Wave Life Sciences Ltd | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Biohaven Ltd | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Precision Biosciences Inc | Company report | 85% |
| Affimed N v | Company report | 85% |
| Bolt Biotherapeutics Inc | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Kiniksa Pharmaceuticals International Plc | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Ultragenyx Pharmaceutical Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Theravance Biopharma inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| Sage Therapeutics Inc | Company report | 85% |
| Xencor Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Point Biopharma Global Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Point Biopharma Global Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Precigen Inc | Reportable 100.00 % |
| Uniqure N v | Single Reportable Segment 100.00 % |
| 2seventy Bio Inc | Reportable 100.00 % |
| Cartesian Therapeutics Inc | Operating 100.00 % |
| Abeona Therapeutics Inc | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Point Biopharma Global Inc .
Point Biopharma Global Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Point Biopharma Global Inc | 1,322 | 2,436,927 | 965,512 |
| Novartis Ag | 319,173 | 752,973 | 185,566 |
| Roivant Sciences Ltd | 29,689 | 10,043 | -552,803 |
| Merus N v | 6,811 | 539,105 | -3,629,857 |
| Edgewise Therapeutics inc | 5,010 | - | -1,350,836 |
| Forte Biosciences Inc | 1,634 | - | -3,823,348 |
| PEERS TOTAL | 368,889 | 725,944 | 137,257 |
Sign in to see all peers for Point Biopharma Global Inc .
Point Biopharma Global Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (446 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.92 % (avg) | -37.9 pp |
| Operating Margin | 44.23 % | industry median | +127.7 pp |
| EBITDA Margin | 56.65 % | -6.30 % (avg) | +63.0 pp |
| Capital Intensity (Capex / Revenue) | 7.93 % | 7.51 % (avg) | +0.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Point Biopharma Global Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 7.8x | 26.5x | -18.8x |
| EV / EBITDA | 5.5x | 15.4x | -9.9x |
| P/B | 1.9x | 4.2x | -2.3x |
| Return on Equity | 21.10 % | industry aggregate | 9.64 % |
| Return on Invested Capital | 11.63 % | -9.78 % (avg) | 21.41 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Point Biopharma Global Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | - | -15.11 % | 19.98 % |
| P/E | - | - | 7.5x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Point Biopharma Global Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 7.93 % vs industry average 7.51 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Point Biopharma Global Inc's dedicated Suppliers and Customers pages, not here.
Point Biopharma Global Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Point Biopharma Global Inc falls in the Low attractiveness / High strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Point Biopharma Global Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 127.7 points above the industry median.
- Return on equity 9.6 points above the industry aggregate.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-95.4% annualized vs trailing 12 months).
Opportunities
- Trades at a lower P/E than the industry average (7.8x vs 26.5x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (59.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-98.9% annualized).
Methodology: see Methodology: SWOT Analysis.
Point Biopharma Global Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Point Biopharma Global Inc | 2.01 | 7.38 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Roivant Sciences Ltd | 12.24 | 22.90 | - |
| Merus N v | 3.67 | 7.20 | - |
| Edgewise Therapeutics inc | 2.11 | 20.86 | - |
| Forte Biosciences Inc | 5.50 | 5.72 | - |
Sign in to see all peers for Point Biopharma Global Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Point Biopharma Global Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Point Biopharma Global Inc | Q3 2023 | - | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Roivant Sciences Ltd | Q2 2026 | -33.5 % | - |
| Merus N v | Q3 2025 | +3.2 % | - |
| Edgewise Therapeutics inc | Q2 2026 | - | - |
| Forte Biosciences Inc | Q2 2026 | - | - |
| PEERS TOTAL | +9.5 % | +22.3 % |
Sign in to see all peers for Point Biopharma Global Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Point Biopharma Global Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Point Biopharma Global Inc | Q3 2023 | - | -16.1 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Roivant Sciences Ltd | Q2 2026 | - | -89.6 % |
| Merus N v | Q3 2025 | - | +21.0 % |
| Edgewise Therapeutics inc | Q2 2026 | - | - |
| Forte Biosciences Inc | Q2 2026 | - | - |
Sign in to see all peers for Point Biopharma Global Inc .
Point Biopharma Global Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Point Biopharma Global Inc | 18.28% | 20.60% | 21.10% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Roivant Sciences Ltd | - | - | - |
| Merus N v | - | - | - |
| Edgewise Therapeutics inc | - | - | - |
| Forte Biosciences Inc | - | - | - |
Sign in to see all peers for Point Biopharma Global Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Point Biopharma Global Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Point Biopharma Global Inc | 11.68 | 5.43 |
| Novartis Ag | 22.82 | 5.63 |
| Roivant Sciences Ltd | - | 3,941.69 |
| Merus N v | - | 120.32 |
| Edgewise Therapeutics inc | - | - |
| Forte Biosciences Inc | - | - |
| PEERS AVERAGE | 33.84 | 6.43 |
Sign in to see all peers for Point Biopharma Global Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.